Development and activities of the BR96-doxorubicin immunoconjugate.
Hellström
I
I
Pacific Northwest Research Institute, Seattle, WA, USA.
Hellström
K E
KE
Senter
P D
PD
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology*; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D003630:Daunorubicin / Q000737:chemistry / Q000494:pharmacology; D004064:Digestive System / Q000276:immunology; D004317:Doxorubicin / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D007983:Lewis Blood Group Antigens / Q000276:immunology*; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009928:Organ Specificity; D051381:Rats; D011914:Rats, Inbred BN; D011923:Rats, Nude; D017211:Treatment Failure; D023041:Xenograft Model Antitumor Assays
D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C092612:BR96-doxorubicin immunoconjugate; D000922:Immunotoxins; D007983:Lewis Blood Group Antigens; C094162:Lewis Y antigen; D004317:Doxorubicin; D003630:Daunorubicin